Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.
Dr. Anjlee Agarwal, is a National Award recipient and a pioneer in universal accessibility and sustainable mobility. In conversation with The Navhind Times, ...
Quadriplegic and bedridden in a prefabricated home, 36-year-old Li Xia can only move one finger and one toe -- yet he runs a ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...
Unified Sports brings students of all abilities together for the love of the game. For one student at Wallenpaupack High ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases. Read why I am bullish about DYN ...
Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.
Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results